Elizabeth Phillips describes their phase 2 trial showing that the combination of inotuzumab ozogamicin and R-CVP is efficacious for certain subgroups of treatment-naïve, R-CHOP-ineligible patients with diffuse large B-cell lymphoma, and outlines the next steps to improve treatment outcomes (5:59).
Nilanjan Ghosh shares phase 1b trial findings showing high response rates with lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell agent, as second-line therapy in patients with aggressive, relapsed or refractory, large B-cell non-Hodgkin lymphomas who were ineligible for haematopoietic stem cell transplantation (6:46).
Matthew Wilson outlines the key results of their study evaluating the optimal timing for administering high-dose methotrexate to reduce the risk of central nervous system relapse in patients with diffuse large B-cell lymphoma (6:13).
Charles Herbaux presents the primary analysis of the phase 2 GATA study showing the potential of combining atezolizumab, obinutuzumab and venetoclax for the treatment of relapsed or refractory diffuse large B-cell lymphoma (5:11).
The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.
Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.